RecruitingNCT06757257

Special Drug Use-results Survey for Long-term Use (Fostamatinib)


Sponsor

Kissei Pharmaceutical Co., Ltd.

Enrollment

149 participants

Start Date

May 29, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.


Eligibility

Inclusion Criteria1

  • Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGfostamatinib

oral administration


Locations(1)

Research site

Tokyo and Japanese Other Cities, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06757257